In contrast, the study of Lendínez-Cano et al. confirmed the moderate performance of the SelectMDx test in detecting clinically significant prostate cancer (ISUP > 1) in patients with PSA levels of 3–10 ng/mL and normal DRE results. This evidence concerns the gene KLK3 and Familial prostate cancer.